Home LiteratureArticle Details
PMID: 21822789 Published · ppublish English Letter Research Support, Non-U.S. Gov't

No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.

Diabetologia ·Vol. 54 ·No. 10 ·2011-10-00 ·Pages 2736-8

Iafusco D, Bizzarri C, Cadario F, Pesavento R, Tonini G, Tumini S, Cauvin V, Colombo C, Bonfanti R, Barbetti F

Abstract

暂无摘要

MeSH Terms
Diabetes Mellitus/drug therapy,genetics Glyburide/therapeutic use Humans Hypoglycemic Agents/therapeutic use Infant, Newborn Mutation Potassium Channels, Inwardly Rectifying/genetics
Chemicals
Hypoglycemic Agents Kir6.2 channel Potassium Channels, Inwardly Rectifying Glyburide
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Iafusco D
Bizzarri C
Cadario F
Pesavento R
Tonini G
Tumini S
Cauvin V
Colombo C
Bonfanti R
Barbetti F
References (10)
10 references, click to expand
  1. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Clin Pharmacol Ther. 2002 Apr;71(4):286-96 PMID: 11956512
  2. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
    PLoS Med. 2008 Oct 28;5(10):e206 PMID: 18959471
  3. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
    Diabet Med. 1998 Apr;15(4):297-303 PMID: 9585394
  4. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.
    Diabetes Technol Ther. 2010 May;12(5):387-91 PMID: 20184447
  5. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Neurology. 2007 Sep 25;69(13):1342-9 PMID: 17652641
  6. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.
    Arq Bras Endocrinol Metabol. 2010 Nov;54(8):682-4 PMID: 21340152
  7. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    N Engl J Med. 2006 Aug 3;355(5):467-77 PMID: 16885550
  8. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Diabetologia. 2006 Sep;49(9):2210-3 PMID: 16816952
  9. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
    Diabetes Care. 2008 Feb;31(2):204-9 PMID: 18025408
  10. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.
    J Clin Endocrinol Metab. 2008 Mar;93(3):1054-61 PMID: 18073297
Article Info
Journal
Diabetologia
Abbr.
Diabetologia
ISSN
1432-0428
DOI
10.1007/s00125-011-2273-7
Published
2011-10-00
Epub
2011-00-07
Pages
2736-8
Language
English
Region
Germany
NLM ID
0006777
Subset
IM
External Links
PubMed source DOI: 10.1007/s00125-011-2273-7 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2